Budapest

The trials here

What the 8 trials at this site are about, from their registry records.

Conditions

• Multiple myeloma2 trials
• Ulcerative colitis2 trials
• Asthma1 trial
• Crohn's disease1 trial
• Hidradenitis suppurativa1 trial
• Multiple sclerosis1 trial

Phase

• Phase 36 trials
• Phase 21 trial
• Phase 41 trial

Status

• Completed3 trials
• Recruiting3 trials
• Active, not recruiting1 trial
• Terminated1 trial

Lead sponsor

• Sanofi8 trials

Running trials

• Recruiting

  A Maintenance Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Ulcerative Colitis

  NCT07185009· Phase 3· Sanofi· Source

• Recruiting

  An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Ulcerative Colitis

  NCT07184996· Phase 3· Sanofi· Source

• Recruiting

  An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease

  NCT07184931· Phase 3· Sanofi· Source

• Active, not recruiting

  SC Versus IV Isatuximab in Combination With Pomalidomide and Dexamethasone in RRMM

  NCT05405166· Phase 3· Sanofi· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Ulcerative colitis2 recruiting
• Crohn's disease1 recruiting

Closed trials

• Terminated

  Proof-of-concept Study Evaluating Subcutaneous Amlitelimab in Adult Participants With Moderate to Severe Hidradenitis Suppurativa

  NCT06118099· Phase 2· Sanofi· Source

• Completed

  EValuating trEatment RESponses of Dupilumab Versus Omalizumab in Type 2 Patients

  NCT04998604· Phase 4· Sanofi· Source

• Completed

  Nonrelapsing Secondary Progressive Multiple Sclerosis (NRSPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168) (HERCULES)

  NCT04411641· Phase 3· Sanofi· Source

• Completed

  Multinational Clinical Study Comparing Isatuximab, Carfilzomib And Dexamethasone To Carfilzomib And Dexamethasone In Relapse And/Or Refractory Multiple Myeloma Patients

  NCT03275285· Phase 3· Sanofi· Source